Vigorous Stocks Need to Consider: Bristol-Myers Squibb (NYSE:BMY), Sangamo BioSciences (NASDAQ:SGMO)

Bristol-Myers Squibb Company (NYSE:BMY) [Trend Analysis] retains strong position in active trade, as shares scoring -0.38% to $59.72 in a active trade session, while looking at the shares volume, around 362845 shares have changed hands in this session. Bristol-Myers Squibb Co. (BMY) and GeneCentric Diagnostics, Inc. reported a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform or CSP might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials.Additionally, GeneCentric said it has secured equity funding from Bristol-Myers Squibb that will support the clinical development of GeneCentric’s CSP and build-out of GeneCentric’s new laboratory in Research Triangle Park.CSP, GeneCentric’s proprietary core technology, identifies biologic subtypes of cancer through an integrated analysis of tumor genomics.

Cancer subtypes can support rational clinical trial design, as biomarkers to identify patient cohorts optimally suited for certain therapeutic compounds, and as companion diagnostics. The firm has institutional ownership of 70.10%, while insider ownership included 0.10%. BMY attains analyst recommendation of 2.30 with week’s performance of 2.45%. Investors looking further ahead will note that the Price to next year’s EPS is 4.16%.

Sangamo BioSciences, Inc. (NASDAQ:SGMO) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 1.23% to 3.69 with around 85346 shares have changed hands in this session. Sangamo Therapeutics, Inc. (SGMO) reported that it has changed its corporate name, from “SangamoBioSciences, Inc.” to “Sangamo Therapeutics, Inc.” Sangamo common stock will continue to trade on the NASDAQ Global Select Market under the current ticker symbol: “SGMO.”

The new corporate name underscores Sangamo’s focus on clinical development of genomic therapies using the Company’s industry-leading platform technologies across genome editing, gene therapy, gene regulation and cell therapy. The stock is going forward its fifty-two week low with 39.43% and lagging behind from its 52-week high price with -54.55%.

Similar, the positive performance for the quarter recorded as -16.28% and for the year was -52.29%, while the YTD performance remained at 19.67%. SGMO has Average True Range for 14 days of 0.30.


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *